Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection

[1]  J Alfred Witjes,et al.  Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. , 2016, European urology.

[2]  Jim C Hu,et al.  Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. , 2015, Urologic oncology.

[3]  U. Capitanio,et al.  More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. , 2015, European urology.

[4]  B. Trock,et al.  Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30‐year experience , 2013, The Prostate.

[5]  P. Walsh,et al.  Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. , 2013, Urology.

[6]  F. Montorsi,et al.  Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  K. Haustermans,et al.  Mapping of pelvic lymph node metastases in prostate cancer. , 2013, European urology.

[8]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[9]  U. Capitanio,et al.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. , 2012, European urology.

[10]  M. Borghesi,et al.  The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate‐ and high‐risk prostate cancer , 2011, BJU international.

[11]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Montorsi,et al.  Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. , 2009, International journal of radiation oncology, biology, physics.

[13]  M. Desai,et al.  The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy , 2009, BJU international.

[14]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  U. Studer,et al.  Detection of occult lymph node metastases in locally advanced node-negative prostate cancer , 2007, Nature Clinical Practice Urology.

[16]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[17]  B. Konety,et al.  Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. , 2006, Urology.

[18]  P. Scardino,et al.  The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. , 2006, The Journal of urology.

[19]  M. Cooperberg,et al.  The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  James A Hanley,et al.  Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.

[21]  E. Bergstralh,et al.  The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. , 2005, The Journal of urology.

[22]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[23]  A. Haese*,et al.  Stage Migration in Clinically Localized Prostate Cancer , 2000, European Urology.

[24]  B. Davis,et al.  Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. , 2016, European urology.

[25]  T. Wiegel,et al.  PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer. , 2015, European urology.

[26]  P. Scardino,et al.  Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. , 2014, European urology.

[27]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[28]  C. Lawton.  Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .

[29]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.